Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
Swords
R
R
Hayden
P J
PJ
Molloy
K
K
Lawlor
M
M
Browne
P V
PV
Murphy
P T
PT
D000208:Acute Disease; D000293:Adolescent; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D000079982:Gemtuzumab; D006801:Humans; D007116:Immunization, Passive; D018796:Immunoconjugates / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D012074:Remission Induction; D016879:Salvage Therapy; D063268:Sialic Acid Binding Ig-like Lectin 3; D014184:Transplantation, Homologous
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D018796:Immunoconjugates; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab